LPCN Lipocine Inc.

4.18
0  0%
Previous Close 4.19
Open 4.19
Price To book 2.97
Market Cap 77.72M
Shares 18,594,000
Volume 104,078
Short Ratio 16.27
Av. Daily Volume 137,813

SEC filingsSee all SEC filings

  1. 8-K - Current report 17683956
  2. 424B5 - Prospectus (Rule 424(b)(5)) 17667930
  3. 8-K - Current report 17667906
  4. 8-K - Current report 17667863
  5. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17667848

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data released September 2016. End of Phase 2 meeting with FDA anticipated for 2H 2017.
LPCN 1111
Oral testosterone product
CRL issued June 2016. Dosing flexibility trial to be initiated 1Q 2017 with data due in 2Q 2017.
LPCN 1021
Men with low testosterone (Low T)
Phase 3 protocol to be filed with FDA 1H 2017.
LPCN 1107
Prevention of preterm birth ("PTB").

Latest News

  1. Lipocine to Present at 27th Annual Oppenheimer Conference
  2. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  3. LPCN: Conserving Cash to Fund Underway DV and DF Studies
  4. LIPOCINE INC. Financials
  5. LIPOCINE INC. Files SEC form 8-K, Other Events
  6. LIPOCINE INC. Files SEC form 10-K, Annual Report
  7. Lipocine Announces Financial and Operational Results for the Full Year of 2016
  8. Lipocine to Present at 29th Annual ROTH Conference
  9. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  10. Lipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer
  11. LIPOCINE INC. Files SEC form 8-K, Change in Directors or Principal Officers
  12. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  13. Lipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth
  14. LPCN: Early Start to Tlando Validation Trial
  15. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  16. Lipocine Initiates a Dosing Flexibility Study for LPCN 1021, Its Oral Testosterone Replacement Product Candidate
  17. Lipocine, Inc. :LPCN-US: Earnings Analysis: Q3, 2016 By the Numbers : December 6, 2016
  18. LIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  19. LPCN Gets Lean Guiding Tlando Through Approval Process.
  20. LIPOCINE INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial

SEC Filings

  1. 8-K - Current report 17683956
  2. 424B5 - Prospectus (Rule 424(b)(5)) 17667930
  3. 8-K - Current report 17667906
  4. 8-K - Current report 17667863
  5. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17667848
  6. 8-K - Current report 17612932
  7. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17612217
  8. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17581991
  9. 8-K - Current report 17560307
  10. 8-K - Current report 17559183